

19 March 2026



ImmuPharma PLC
("ImmuPharma" or the "Company")

Publication of Circular

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that further to its 'Fundraising' announcement, published on 17 March 2026 at 7:00 a.m. (the "**Fundraising RNS**"), a circular convening a General Meeting has today been sent to shareholders.

The General Meeting is scheduled to be held at 11.00 a.m. on 7 April 2026, at the offices of Broadfield Law UK LLP, One Bartholomew Close, London EC1A 7BL at 11.00 a.m. (GMT).

A copy of the Circular will be available shortly, in electronic form, for download on the Company's website www.immupharma.co.uk.

Terms used but not defined in this announcement have the same meaning as set out in the Fundraising RNS.

For further information, please contact:

ImmuPharma PLC (www.immupharma.co.uk)	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)	+44 (0) 203 368 3550
Neil Baldwin	
Stanford Capital Partners (Joint Broker)	44 (0) 20 3650 3650
Patrick Claridge, Bob Pountney	
SI Capital (Joint Broker)	+44 (0) 1483 413500
Nick Emerson	

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.